Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864024 | 1.00 | CA2 (0.32) | CA2CA4DRD4HDAC1HDAC6 | |
| SCHEMBL14448983 | 0.83 | CA2 (0.32) | CA2CA4DRD4HDAC1HDAC6 | |
| SCHEMBL16825606 | 0.82 | DRD4 (0.37) | CA2CA4DRD4 | |
| SCHEMBL29669073 | 0.82 | DRD4 (0.37) | CA2CA4DRD4 | |
| SCHEMBL29864532 | 0.81 | ACHE (0.31) | ACHE | |
| SCHEMBL19947979 | 0.81 | ACHE (0.31) | ACHE | |
| SCHEMBL1166843 | 0.78 | ENPP2 (0.33) | P2RX7ACHE | |
| SCHEMBL19810453 | 0.75 | NOTUM (0.33) | CA2CA4DRD4P2RX7ALDH1A1 | |
| SCHEMBL18070215 | 0.75 | CYP1A2 (0.35) | — | |
| SCHEMBL26547553 | 0.75 | ALDH1A1 (0.37) | CA2CA4DRD4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2021076902-A1 | INHIBITING HUMAN INTEGRIN α 4 β 7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| CN-111989321-A | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-20200262837-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | CA2 3669/4885CA4 688/4885DRD4 1749/4885 |
| US-10689377-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CA2 2065/4885CA4 3820/4885DRD4 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.